PBMNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBMWW
PSYENCE BIOMEDICAL LTD.
Financials through Q2 FY2026, quarter ended Sep 30, 2025Last filing: 20-F on Jun 22, 2026
$4.12−0.10 (-2.37%)
Close on Oct 19, 2026
- Market cap
- $6.10M
- P/E (TTM)
- 0.8
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Sep 30, 2025
Psyence Biomedical reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Psyence Biomedical's annual report. Trading prices and yields need FINRA TRACE data.